AAX Biotech

AAX Biotech AB is a biotechnology company focused on next-generation antibody therapies. The company offers two unique and proprietary technologies—Seqitope® and Opti-mAb®—which enable high-throughput, high-resolution epitope mapping and stabilization of single-chain variable fragments (scFv), applicable in bispecific antibodies and CAR-T cell therapies, among others. Both technologies aim to produce better and more effective antibody-based drugs. These innovations position AAX Biotech as a key player in the rapidly growing antibody therapy market. AAX Biotech was founded by experts from the Karolinska Institute in Stockholm, Sweden.